Fluorescein Angiography for Age-Related Macular Degeneration
What Is Fluorescein Angiography?
Fluorescein angiography (FA) is a specialized eye imaging procedure that maps blood flow through the retina and the layer beneath it called the choroid. It uses an injected dye and a specially designed camera to reveal details about blood vessels that standard eye exams and other imaging tests cannot show.
During the procedure, a small amount of fluorescein dye is injected into a vein in your arm. The dye travels through your bloodstream and reaches the blood vessels in your eyes within seconds. A retinal camera then takes a rapid series of photographs as the dye passes through.
The fluorescein dye glows brightly when exposed to blue light from the camera. Healthy blood vessels keep the dye contained within their walls. Abnormal or fragile vessels allow the dye to leak out into surrounding tissue, and this leakage appears as expanding bright areas in the images. Retina specialists review these images in early and late phases to understand how blood is moving and where problems are occurring.
Optical coherence tomography (OCT) is another imaging test commonly used in AMD care. OCT creates detailed cross-sectional pictures of the retina's layers and is very effective at detecting fluid buildup and measuring retinal thickness. However, it does not directly show whether blood vessels are actively leaking or identify the precise source of that leakage.
Fluorescein angiography and OCT provide different, complementary types of information. While OCT is often used for routine monitoring because it does not require a dye injection, fluorescein angiography remains essential for classifying AMD, especially the wet form, and for answering questions that OCT alone cannot resolve.
Why This Test Matters for AMD
Fluorescein angiography is particularly important in the care of AMD because the disease exists in two very different forms that require very different responses. Identifying which form is present, and understanding exactly how it is behaving, directly shapes every decision about your care.
Dry AMD involves the gradual breakdown of light-sensitive cells in the macula. Wet AMD occurs when abnormal new blood vessels grow beneath the retina and begin leaking fluid or blood, which can rapidly damage central vision. Fluorescein angiography is the most effective test for confirming wet AMD and distinguishing it from the dry form.
This distinction matters greatly because wet AMD requires prompt treatment to prevent serious vision loss, while dry AMD is managed differently and monitored over time.
The hallmark of wet AMD is a process called choroidal neovascularization (CNV), which refers to the growth of new, fragile blood vessels from the choroid layer into or beneath the retina. These vessels are the primary cause of severe vision loss in wet AMD.
During fluorescein angiography, CNV appears as an area of brightness that starts early in the imaging sequence and expands in both size and intensity over time. This expanding pattern distinguishes active CNV from areas of retinal atrophy, which also appear bright early in the test but do not grow beyond their original borders. Recognizing this difference is essential for choosing the right treatment approach.
The specific pattern of leakage seen on fluorescein angiography helps your retina specialist determine the most appropriate course of treatment. The test reveals where the abnormal vessels are located in relation to the center of the macula, how large the affected area is, and where the boundaries of the leaking zone lie.
Currently approved medications for wet AMD include aflibercept (Eylea), ranibizumab (Lucentis), faricimab (Vabysmo), and brolucizumab (Beovu). Bevacizumab (Avastin) is also widely used off-label. The angiographic findings can help guide which medication and injection schedule may be most appropriate for your situation.
OCT angiography (OCTA) is a newer imaging technique that can visualize blood flow without a dye injection. While useful, OCTA has known limitations. It can struggle to image blood flow beneath certain types of retinal pigment detachments, and it may miss details in more complex presentations of CNV.
In these situations, fluorescein angiography provides the complete diagnostic picture that guides care. Both OCT and fluorescein angiography are recognized as valid tools for monitoring AMD treatment response, reflecting how these technologies work together rather than one replacing the other.
Who Should Have This Test
Fluorescein angiography is not needed by every patient with AMD at every visit. Our specialists recommend it when it will provide information that changes or refines your care in a meaningful way.
Fluorescein angiography is recommended for patients who have AMD and develop symptoms that may indicate CNV. These include metamorphopsia (distorted or wavy vision), a new scotoma (a dark or missing spot in central vision), or unexplained vision loss. Clinical signs such as retinal bleeding, fluid beneath the retinal pigment layer, or fatty deposits from leaking vessels also prompt evaluation.
Not all patients notice symptoms immediately when wet AMD begins. Those who are at high risk for progression from dry to wet AMD may need this test even without new complaints, based on findings during a dilated eye exam.
AMD is the leading cause of significant central vision loss in people over age 50 in developed countries. Risk factors for progression include advancing age, smoking, family history of AMD, and certain genetic factors.
Patients already diagnosed with AMD in one eye are at higher risk for developing the condition in the other eye. Our retina specialists, including Dr. Gaurav Gupta and Dr. Pranjal Thakuria, work closely with at-risk patients to monitor for early signs of progression and intervene as quickly as possible when CNV develops.
For patients receiving anti-VEGF injections who are not improving as expected, fluorescein angiography can help uncover why. The test may reveal persistent or recurrent CNV, a different subtype of abnormal blood vessel growth, or a separate condition that is also contributing to vision changes.
This additional information allows your retina specialist to adjust your treatment plan rather than continuing an approach that is not working effectively.
What to Expect During the Procedure
Most patients find fluorescein angiography to be a straightforward experience. Knowing what will happen at each step can help you feel more comfortable on the day of your appointment.
Our team will review your medical history and ask about any known allergies, including prior reactions to dyes. Dilating eye drops will be placed in your eyes to widen the pupils, which allows the camera to capture the full retina. Dilation usually takes 20 to 30 minutes to reach full effect.
We recommend bringing sunglasses to your appointment, as your eyes will remain sensitive to light for several hours afterward. You may also want to arrange for someone to drive you home, since your vision will be temporarily blurred from the dilation drops.
A technician will place a small needle into a vein in your arm or hand, similar to a standard blood draw. The fluorescein dye is then injected, and within seconds it reaches the blood vessels in your eyes. The camera takes a rapid series of photographs as the dye flows through your retinal circulation.
You may be asked to look in different directions so the photographer can capture all areas of the retina. Most patients notice a brief warm sensation when the dye is injected. The imaging process itself is not painful, and the entire procedure generally takes about 10 minutes. Additional late-phase images are sometimes captured five to ten minutes after the initial injection.
After your appointment, your skin may appear slightly yellow for a few hours, and your urine will turn bright orange or yellow for one to two days. This is a normal sign that your body is clearing the fluorescein dye, and drinking plenty of water helps speed that process along.
Most patients return to their normal activities the same day. Your retina specialist will review the images and discuss the results with you, either at the same visit or at a scheduled follow-up appointment.
Fluorescein angiography is considered a safe procedure for the vast majority of patients. The most common side effect is mild, temporary nausea, which affects a small percentage of patients. Rarely, some patients may experience an allergic reaction to the dye, ranging from mild hives to more serious responses.
Please inform our team before the test if you have a known allergy to fluorescein dye or have had a previous reaction to it. Patients who are pregnant should discuss the potential risks and benefits with their specialist, as the safety of fluorescein during pregnancy has not been fully established. Our team will have appropriate precautions in place throughout the procedure.
How Results Connect to Your AMD Treatment
Fluorescein angiography does not just diagnose wet AMD. It serves as an active tool throughout your treatment journey, from your very first evaluation through long-term management of the condition.
Before treatment begins, your retina specialist uses fluorescein angiography to document the location, size, and type of CNV present. This initial angiogram creates a baseline that the care team can refer back to when evaluating whether treatment is working over time.
Without this reference point, it would be difficult to objectively measure whether the abnormal blood vessels have responded to therapy. The baseline FA is also useful for choosing the most appropriate anti-VEGF medication for your specific presentation.
For routine follow-up visits, OCT is typically the primary monitoring tool because it is fast, noninvasive, and effective at detecting fluid in and beneath the retina. Fluorescein angiography steps in when OCT findings are uncertain or when vision continues to decline despite ongoing injections.
In these cases, FA can reveal whether leakage is still active, identify new areas of CNV that have developed, or confirm that the abnormal vessels have been successfully closed by treatment. This information directly influences the next steps in your care plan.
Fluorescein angiography is not needed at every clinic visit. For many patients with wet AMD, the test is performed at diagnosis and then repeated only when there is a specific clinical reason, such as a sudden change in vision or evidence of disease progression despite treatment.
As imaging technologies continue to evolve, fluorescein angiography remains a foundational diagnostic tool. Its unique ability to directly visualize dye leakage from abnormal blood vessels gives it a role that other technologies, including OCTA, have not fully replaced in complex or challenging cases.
Warning Signs That Need Prompt Attention
Knowing when to seek care quickly is one of the most important parts of managing AMD. Some changes in your vision are urgent, and acting fast can make a real difference in preserving your sight.
If you experience a sudden increase in floaters, new flashes of light, a curtain or shadow across your vision, or sudden vision loss in either eye, seek care right away. These symptoms may signal a serious change in your condition that needs same-day evaluation. Do not wait for a routine appointment if you notice these warning signs.
If you have been diagnosed with dry AMD and begin to notice that straight lines look wavy or bent (metamorphopsia), a dark or blurry area in the center of your vision, or difficulty reading even with your current glasses, contact our office promptly. These changes may indicate that choroidal neovascularization has developed.
Early detection of wet AMD through timely fluorescein angiography gives anti-VEGF treatment the best opportunity to preserve your remaining central vision. Delays in diagnosis can allow the condition to progress significantly.
If you are over age 50 and have risk factors for AMD, regular dilated eye exams are important even when your vision feels stable. An optometrist or ophthalmologist can screen for early changes and refer you to a retina specialist when needed.
Using an Amsler grid at home, a simple card with a grid of straight lines, can help you monitor your central vision between appointments. If you notice any new distortion, missing areas, or waviness on the grid, contact your retina specialist promptly rather than waiting for your next scheduled visit.
Frequently Asked Questions
Below are answers to questions our patients commonly ask about fluorescein angiography and its role in AMD care.
The needle stick used to inject the dye may cause brief, mild discomfort similar to a routine blood draw, but the imaging portion of the test is not painful. Some patients notice a short warm sensation throughout their body as the dye is injected, and a small number experience mild nausea that passes quickly. These effects are temporary, and our team monitors you throughout the procedure to make sure you are comfortable.
The frequency depends entirely on your individual situation. Many patients with wet AMD have the test at the time of diagnosis and then only when something clinically significant changes, such as a shift in symptoms, an unclear OCT result, or a lack of response to injections. There is no single schedule that applies to everyone. Your specialist will determine when a repeat FA adds meaningful information beyond what routine monitoring with OCT already shows.
Fluorescein angiography can identify features of both forms of AMD, but it is most clinically valuable for diagnosing and characterizing wet AMD. In dry AMD, the appearance of the images remains stable throughout the phases of the test, with any bright areas staying consistent in size. In wet AMD, the characteristic expanding leakage pattern from CNV is the key diagnostic finding. For ongoing monitoring of dry AMD without suspected CNV, OCT is typically the preferred and more practical imaging tool.
Most patients tolerate fluorescein angiography well, but there are situations where extra caution is appropriate. Patients with a known prior allergic reaction to fluorescein dye should discuss this with their specialist before the test, as alternatives or precautions may be considered. Pregnant patients should have a careful conversation with their specialist about the potential risks and benefits, since the safety of fluorescein during pregnancy has not been fully established. Being upfront about your medical history allows our team to plan appropriately.
OCT has taken over many routine monitoring functions because it is fast, noninvasive, and excellent at detecting retinal fluid, but it has not replaced fluorescein angiography. The two tests answer different clinical questions. OCT measures structural changes in the retina's layers, while FA directly shows which vessels are leaking and maps the exact extent and pattern of that leakage. In complex cases, uncertain diagnoses, or situations where treatment is not working as expected, FA provides information that OCT and even OCTA cannot reliably deliver on their own.
If fluorescein angiography confirms active choroidal neovascularization, your retina specialist will discuss treatment options with you at that visit or a closely scheduled follow-up. For most patients, treatment with anti-VEGF eye injections begins promptly because earlier intervention is associated with better outcomes. The angiographic images will also help determine the most appropriate medication and give the team a baseline for measuring your response over time. You will not be left waiting without a clear next step.
Trusted Retina Care at Rhode Island Eye Institute
Our retina specialists at Rhode Island Eye Institute have the training, technology, and experience to evaluate and manage AMD with precision and compassion. Whether you need a first-time evaluation, a second opinion, or ongoing care for wet AMD, our team is here to help you understand your condition and protect your vision. We welcome patients from across the region and are committed to providing the personalized, expert care you deserve. Contact us today to schedule your appointment.